Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Daiichi Sankyo's R&D leaders are optimistic about how the Factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products.
Advertisement

Related Content

ROCKET AF: Positive Results For Xarelto, But A Few Chinks In The Armor
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup

Topics

Advertisement
UsernamePublicRestriction

Register

PS004619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel